KRAS and non-small cell lung carcinoma: Recently, immune checkpoint inhibitors (ICIs) that target programmed cell death protein-1 (PD-1)/PD ligand-1 (PD-L1) axis have significantly prolonged survival outcomes of patients with metastatic NSCLC, especially for patients with KRAS mutations [3].